NCT03467984

A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants

A Single-blind, Multi-center, Randomized, Active-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Immunogenicity of Intramuscular Three Injections With LBVE(Multivalent Pneumococcal Conjugate Vaccine) Compared to Prevnar13 in Healthy Infants

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 230 (actual)
• Sponsor: LG Chem · Industry
• Sex: All
• Age: 6 Weeks – 8 Weeks
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety and immunogenicity of LBVE (Multivalent Pneumococcal Conjugate Vaccine) in healthy infants.

Conditions

• Pneumococcal Infection

Interventions

Type	Name	Description
BIOLOGICAL	LBVE	Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
BIOLOGICAL	Prevnar13	13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh

Timeline

• Start date: 2018-05-25
• Primary completion: 2018-10-05
• Completion: 2019-03-27
• First posted: 2018-03-16
• Last updated: 2019-08-22

Locations

1 site across 1 country: South Korea